Jihyun Kim1, Junshik Hong2, Seog Gyun Kim1, Kyung Hoon Hwang1, Minsu Kim2, Hee Kyung Ahn2, Sun Jin Sym2, Jinny Park2, Eun Kyung Cho2, Dong Bok Shin2, Jae Hoon Lee2. 1. Department of Nuclear Medicine, Gachon University Gil Medical Center, Gachon Univsersity School of Medicine, 21 Namdongdae-ro 774-gil, Namdong-gu, Incheon 405-760 Republic of Korea. 2. Department of Internal Medicine, Gachon University Gil Medical Center, Gachon Univsersity School of Medicine, 21 Namdongdae-ro 774-gil, Namdong-gu, Incheon 405-760 Republic of Korea.
Abstract
PURPOSE: The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by (18)F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-containing immunochemotherapy. METHODS: Patients with newly diagnosed DLBCL who underwent pre-treatment torso FDG-PET/CT scan taken within 10 days before treatment were included. MTV was defined as the volume of hypermetabolic tissue with a standardized uptake value (SUV) greater than a threshold value of 2.5 and calculated using volume viewer software. Association of MTV with patient characteristics and survival were compared. RESULTS: A total of 96 patients were evaluated. During a median follow-up period of 27.8 months, 3-year event-free survival (EFS) and overall survival was 69.5 % and 72.9 %, respectively. The Ann Arbor staging showed a limitation of prognosis because there was no difference of EFS between patients with Ann Arbor stage II and those with stage III. On the contrary, among patients with Ann Arbor stage II or III disease (n = 53), the higher MTV group showed significantly inferior EFS compared with the lower MTV group. CONCLUSIONS: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease.
PURPOSE: The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by (18)F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-containing immunochemotherapy. METHODS:Patients with newly diagnosed DLBCL who underwent pre-treatment torso FDG-PET/CT scan taken within 10 days before treatment were included. MTV was defined as the volume of hypermetabolic tissue with a standardized uptake value (SUV) greater than a threshold value of 2.5 and calculated using volume viewer software. Association of MTV with patient characteristics and survival were compared. RESULTS: A total of 96 patients were evaluated. During a median follow-up period of 27.8 months, 3-year event-free survival (EFS) and overall survival was 69.5 % and 72.9 %, respectively. The Ann Arbor staging showed a limitation of prognosis because there was no difference of EFS between patients with Ann Arbor stage II and those with stage III. On the contrary, among patients with Ann Arbor stage II or III disease (n = 53), the higher MTV group showed significantly inferior EFS compared with the lower MTV group. CONCLUSIONS: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease.
Authors: T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Johannes B Roedl; Rivka R Colen; Nagaraj S Holalkere; Alan J Fischman; Noah C Choi; Michael A Blake Journal: Radiother Oncol Date: 2008-08-11 Impact factor: 6.280
Authors: Jonathan A Abelson; James D Murphy; Nicholas Trakul; Jose G Bazan; Peter G Maxim; Edward E Graves; Andrew Quon; Quynh-Thu Le; Maximilian Diehn; Billy W Loo Journal: Lung Cancer Date: 2012-09-23 Impact factor: 5.705
Authors: Richard B Wilder; Maria A Rodriguez; L Jeffrey Medeiros; Susan L Tucker; Chul S Ha; Jorge E Romaguera; Barbara Pro; Mark A Hess; Fernando Cabanillas; James D Cox Journal: Cancer Date: 2002-06-15 Impact factor: 6.860
Authors: Qaid Ahmed Shagera; Gi Jeong Cheon; Youngil Koh; Min Young Yoo; Keon Wook Kang; Dong Soo Lee; E Edmund Kim; Sung-Soo Yoon; June-Key Chung Journal: Eur J Nucl Med Mol Imaging Date: 2019-04-02 Impact factor: 9.236
Authors: Abhinav K Jha; Esther Mena; Brian Caffo; Saeed Ashrafinia; Arman Rahmim; Eric Frey; Rathan M Subramaniam Journal: J Med Imaging (Bellingham) Date: 2017-03-03
Authors: Mathieu Nessim Toledano; P Desbordes; A Banjar; I Gardin; P Vera; P Ruminy; F Jardin; H Tilly; S Becker Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-17 Impact factor: 9.236
Authors: Sarah A Milgrom; Jihyun Kim; Alin Chirindel; Jongho Kim; Qinglin Pei; Lu Chen; Allen Buxton; Sandy Kessel; Jeffrey Leal; Kathleen M McCarten; Bradford S Hoppe; Suzanne L Wolden; Cindy L Schwartz; Debra L Friedman; Kara M Kelly; Steve Y Cho Journal: Pediatr Blood Cancer Date: 2021-07-10 Impact factor: 3.838